11-Gene Prognostic Signature for Non-M3 AML Treated with VD-CAG

Data Sheet 1 contains results from a multi-omics study of 15 non-M3 acute myeloid leukemia patients treated with the VD-CAG regimen. The dataset includes the 11-gene prognostic signature (TLN1, ARL15, PDZD2, ACER2, IGF2BP3, TMEM200A, DOCK1, SYTL4, CPNE8, FNDC3B, MANBA) validated in the TCGA-LAML and Beat AML cohorts. It was authored by Jirui Tang and last updated on 2026-05-19.

Use Cases

• Validate the 11-gene signature's performance for survival prediction based on the reported hazard ratios and AUC values.
• Analyze gene expression changes associated with VD-CAG treatment response based on the described RNA-seq and proteomic data.
• Investigate the biological pathways (e.g., MAPK signaling, cell adhesion) implicated in treatment response as mentioned in the results.
• Compare prognostic biomarker performance across different AML cohorts (TCGA, Beat AML) using the provided signature.

Strengths

• Includes a validated 11-gene prognostic signature with strong reported performance (HR=3.60, p=7.6e-10 in TCGA cohort).
• Based on integrative multi-omics profiling (RNA-seq and DIA proteomics) from 15 patient samples.
• Externally validated in an independent cohort (Beat AML), with reported 3-year AUC of 0.83.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (1.4 MB), which may limit the scope of secondary analyses.
• Data may reflect bias inherent to the specific patient cohort and treatment regimen studied.

Provenance

Source

figshare, author Jirui Tang.

Collection Method

Integrative multi-omics profiling (RNA sequencing, DIA proteomics) of bone marrow samples from 15 non-M3 AML patients receiving VD-CAG induction therapy.

Freshness

Last updated 2026-05-19 04:22:49; freshness should be verified.